Document is current

Any future updates will be listed below

1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2023-SITC2023.1396

Published Online: 2023-11-02

Published Print: 2023-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark